Kiniksa Pharmaceuticals Valuation
| KNSA Stock | USD 19.66 0.22 1.11% |
At this time, the firm appears to be undervalued. Kiniksa Pharmaceuticals secures a last-minute Real Value of $23.86 per share. The latest price of the firm is $19.66. Our model forecasts the value of Kiniksa Pharmaceuticals from analyzing the firm fundamentals such as Profit Margin of (0.02) %, return on equity of -0.0215, and Current Valuation of 1.22 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Kiniksa Pharmaceuticals' valuation include:
Price Book 3.2845 | Enterprise Value | Enterprise Value Ebitda (44.93) | Price Sales 3.737 | Enterprise Value Revenue 3.182 |
Undervalued
Today
Please note that Kiniksa Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Kiniksa Pharmaceuticals is based on 3 months time horizon. Increasing Kiniksa Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kiniksa Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kiniksa Stock. However, Kiniksa Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.66 | Real 23.86 | Target 36.0 | Hype 19.68 | Naive 20.96 |
The real value of Kiniksa Stock, also known as its intrinsic value, is the underlying worth of Kiniksa Pharmaceuticals Company, which is reflected in its stock price. It is based on Kiniksa Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kiniksa Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kiniksa Pharmaceuticals helps investors to forecast how Kiniksa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kiniksa Pharmaceuticals more accurately as focusing exclusively on Kiniksa Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Kiniksa Pharmaceuticals' intrinsic value based on its ongoing forecasts of Kiniksa Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Kiniksa Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Kiniksa Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Kiniksa Pharmaceuticals Cash |
|
Kiniksa Valuation Trend
Comparing Kiniksa Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Kiniksa Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Kiniksa Revenue by Product
Kiniksa Pharmaceuticals Total Value Analysis
Kiniksa Pharmaceuticals is now projected to have valuation of 1.22 B with market capitalization of 1.44 B, debt of 12.26 M, and cash on hands of 138.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Kiniksa Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.22 B | 1.44 B | 12.26 M | 138.21 M |
Kiniksa Pharmaceuticals Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of Kiniksa Pharmaceuticals was now reported as 6.06. The company has Price/Earnings To Growth (PEG) ratio of 0.25. Kiniksa Pharmaceuticals recorded a loss per share of 0.12. The entity had not issued any dividends in recent years. The firm had 1:1 split on the 28th of June 2024. Based on the key indicators related to Kiniksa Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Kiniksa Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Kiniksa Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kiniksa Pharmaceuticals has an asset utilization ratio of 51.35 percent. This suggests that the Company is making $0.51 for each dollar of assets. An increasing asset utilization means that Kiniksa Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Kiniksa Pharmaceuticals Ownership Allocation
Kiniksa Pharmaceuticals maintains a total of 41.57 Million outstanding shares. The majority of Kiniksa Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kiniksa Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kiniksa Pharmaceuticals. Please pay attention to any change in the institutional holdings of Kiniksa Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost eight hundred seventy-two thousand nine hundred three invesors are currently shorting Kiniksa Pharmaceuticals expressing very little confidence in its future performance.Kiniksa Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 270.26 M. Net Income was 14.08 M with profit before overhead, payroll, taxes, and interest of 234.44 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kiniksa Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kiniksa Pharmaceuticals and how it compares across the competition.
About Kiniksa Pharmaceuticals Valuation
The stock valuation mechanism determines Kiniksa Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Kiniksa Pharmaceuticals. We calculate exposure to Kiniksa Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kiniksa Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 245.8 M | 258.1 M | |
| Pretax Profit Margin | (0.06) | (0.06) | |
| Operating Profit Margin | (0.08) | (0.09) | |
| Net Profit Margin | 0.05 | 0.05 | |
| Gross Profit Margin | 0.71 | 0.62 |
Kiniksa Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 71.9 M | |
| Quarterly Earnings Growth Y O Y | 5.5 |
Kiniksa Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Kiniksa Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Kiniksa we look at many different elements of the entity such as Kiniksa's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Kiniksa Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Kiniksa Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Kiniksa Pharmaceuticals' worth.Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |